In the News
Strength training outperforms aerobic exercise in normal-weight type 2 diabetes patients
A randomized controlled trial in California found that glycemic control and body composition improved more over nine months among normal-weight patients with type 2 diabetes assigned to strength training versus aerobic exercise.
Young adults' lack of regular diabetes care may be linked to beliefs about medication
Follow-up research from the TODAY study found that a quarter of participants, ages 19 to 31 years, lacked a usual place for diabetes care and almost half had an urgent care visit in the past year. Belief in the necessity of medications was associated with regular access to care.
SGLT-2 inhibitors, GLP-1 receptor agonists beat DPP-4s, sulfonylureas in pragmatic trial
Veterans with diabetes who started sodium-glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists had fewer major adverse cardiovascular events than those initiating dipeptidyl peptidase-4 (DPP-4) inhibitors or sulfonylureas.
MKSAP quiz: Evaluation after gastric bypass surgery
This month's quiz asks readers to manage medications for a 46-year-old woman with type 2 diabetes being evaluated 2 months after Roux-en-Y gastric bypass surgery.
Spotlight on diabetes around the world
The global age-standardized prevalence of diabetes is 6.1%, according to an analysis of 204 countries, while other recent studies found diabetes control in China and India to be less than optimal.
In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA1c at 26 wk
Weekly insulin injections might be optimal for patients with type 2 diabetes who are already taking weekly glucagon-like peptide 1 receptor agonists and need additional basal insulin, noted an ACP Journal Club commentary.
SGLT-2 inhibitors reduced gout flares in patients with diabetes, gout
New users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had about half the risk of an ED visit or hospitalization for a gout flare as matched patients taking dipeptidyl peptidase-4 inhibitors, a cohort analysis found.
CBT device for type 2 diabetes receives OK to market
The FDA recently authorized marketing of a prescription-only digital therapeutic device intended to provide cognitive behavioral therapy (CBT) to adult patients with type 2 diabetes.